X

Trial Profile

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atazanavir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Ritonavir (Primary)
Indications HIV infections
Focus Pharmacokinetics

Most Recent Events

05 Jan 2016 Results published in the Antiviral Therapy
05 Jun 2012 Planned end date changed from 1 May 2012 to 1 May 2014 as reported by ClinicalTrials.gov.
14 Apr 2011 Planned End Date changed from 1 May 2011 to 1 May 2012, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com